A nurse is preparing to administer methylergonovine intramuscularly for a client who had a vaginal delivery earlier that day. The nurse should explain to the client that this medication will help prevent which of the following?

Choice A rationale Methylergonovine is an ergot alkaloid derivative that exerts its primary action by directly stimulating α-adrenergic and serotonergic receptors on the uterine smooth muscle, leading to rapid, forceful, and sustained tetanic contractions. While it addresses hemorrhage, it has no significant antimicrobial properties and is therefore not indicated for the prevention of postpartum infection (endometritis), which typically requires broad-spectrum antibiotics. Choice B rationale The primary action of methylergonovine is on the uterus, but it is a potent vasoconstrictor, acting on vascular smooth muscle via α-adrenergic agonism, leading to a risk of hypertension and headache. Therefore, it is contraindicated in clients with pre-existing hypertension or preeclampsia, and explaining it would prevent hypertension is scientifically incorrect as it is a known adverse effect. Choice C rationale Methylergonovine is a potent uterotonic agent that acts by causing sustained, powerful contraction of the myometrium, specifically targeting the α-adrenergic receptors on the uterine smooth muscle. This mechanism constricts the uterine blood vessels (myometrial spiral arteries), which efficiently compresses them, thereby minimizing blood loss and preventing or treating postpartum hemorrhage. Choice D rationale Thromboembolic events (like deep vein thrombosis or pulmonary embolism) are a known risk during the postpartum period due to the hypercoagulable state. While medications like low-molecular-weight heparin are used for prophylaxis, methylergonovine's vasoconstrictive properties, while primarily uterine, do not prevent systemic thrombosis; in fact, the drug can contribute to vascular stasis.